{"id":"https://openalex.org/W4403662848","doi":null,"title":"BIMZELX\u00ae (Bimekizumab-bkzx) Injection, for Subcutaneous Use.","display_name":"BIMZELX\u00ae (Bimekizumab-bkzx) Injection, for Subcutaneous Use.","publication_year":2024,"publication_date":"2024-01-01","ids":{"openalex":"https://openalex.org/W4403662848","pmid":"https://pubmed.ncbi.nlm.nih.gov/39433523"},"language":"en","primary_location":{"id":"pmid:39433523","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39433523","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Skinmed","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100603158","display_name":"Aditya Kumar Gupta","orcid":"https://orcid.org/0000-0002-8664-7723","observed_orcids":["https://orcid.org/0000-0002-8664-7723"]},"institutions":[{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I4210126549","display_name":"Mediprobe Research (Canada)","ror":"https://ror.org/02x3bf117","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210126549"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Aditya K Gupta","raw_affiliation_strings":["Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada","Mediprobe Research Inc., London, Ontario, Canada; aditya.gupta@utoronto.ca"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Dermatology, Department of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada","institution_ids":["https://openalex.org/I185261750"]},{"raw_affiliation_string":"Mediprobe Research Inc., London, Ontario, Canada; aditya.gupta@utoronto.ca","institution_ids":["https://openalex.org/I4210126549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073064001","display_name":"Avantika Mann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126549","display_name":"Mediprobe Research (Canada)","ror":"https://ror.org/02x3bf117","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210126549"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Avantika Mann","raw_affiliation_strings":["Mediprobe Research Inc., London, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mediprobe Research Inc., London, Ontario, Canada","institution_ids":["https://openalex.org/I4210126549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077394930","display_name":"Kimberly Dawn Vincent","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kimberly Vincent","raw_affiliation_strings":["Private Practice, Sevierville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Private Practice, Sevierville, TN","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033724363","display_name":"William Abramovits","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I123534392","display_name":"University of North Texas","ror":"https://ror.org/00v97ad02","country_code":"US","type":"education","lineage":["https://openalex.org/I123534392"]},{"id":"https://openalex.org/I4210160418","display_name":"Baylor Scott & White Health","ror":"https://ror.org/05wevan27","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210160418"]},{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Abramovits","raw_affiliation_strings":["University of Texas Southwestern Medical School, Dallas, TX","Baylor Scott & White University Hospital, Dallas, TX","The University of North Texas Dermatology Residency Program, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas Southwestern Medical School, Dallas, TX","institution_ids":["https://openalex.org/I867280407"]},{"raw_affiliation_string":"Baylor Scott & White University Hospital, Dallas, TX","institution_ids":["https://openalex.org/I4210160418"]},{"raw_affiliation_string":"The University of North Texas Dermatology Residency Program, Dallas, TX","institution_ids":["https://openalex.org/I123534392"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.15895964,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"22","issue":"5","first_page":"370","last_page":"374"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bimekizumab","display_name":"bimekizumab","score":0.9480000138282776},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.8949999809265137},{"id":"https://openalex.org/keywords/il-17a-inhibitor","display_name":"IL-17A inhibitor","score":0.6150000095367432},{"id":"https://openalex.org/keywords/subcutaneous-injection","display_name":"subcutaneous injection","score":0.8339999914169312},{"id":"https://openalex.org/keywords/pasi-90","display_name":"PASI 90","score":0.9269999861717224},{"id":"https://openalex.org/keywords/ustekinumab","display_name":"ustekinumab","score":0.972000002861023},{"id":"https://openalex.org/keywords/adalimumab","display_name":"adalimumab","score":0.9909999966621399},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.5139999985694885},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5270000100135803},{"id":"https://openalex.org/keywords/drug-approval","display_name":"drug approval","score":0.3319999873638153},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.33500000834465027},{"id":"https://openalex.org/keywords/il-23","display_name":"IL-23","score":0.7099999785423279},{"id":"https://openalex.org/keywords/il-22","display_name":"IL-22","score":0.531000018119812}],"concepts":[{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.2906278371810913}],"mesh":[{"descriptor_ui":"D000069549","descriptor_name":"Ustekinumab","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000069549","descriptor_name":"Ustekinumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003879","descriptor_name":"Dermatologic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011565","descriptor_name":"Psoriasis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":1,"locations":[{"id":"pmid:39433523","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/39433523","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Skinmed","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6907897860","https://openalex.org/W3152821140","https://openalex.org/W3128034858","https://openalex.org/W4316927819","https://openalex.org/W4385662437","https://openalex.org/W3128747576","https://openalex.org/W3194367373","https://openalex.org/W3102615618","https://openalex.org/W7166639899","https://openalex.org/W3103727622"],"abstract_inverted_index":{"(bimekizumab-bkzx)":[0],"injection,":[1],"for":[2,10,41],"subcutaneous":[3],"use,":[4],"was":[5,39,52,109,134,172,191,230,249,266],"approved":[6],"in":[7,16,64,114,120,127,139,145,152,177,184,196,203,235,242,254,261],"October":[8],"2023":[9],"moderate":[11],"to":[12],"severe":[13],"plaque":[14,45],"psoriasis":[15],"patients":[17,96,161,212],"aged":[18],"\u226518":[19],"years.":[20],"In":[21,91,156,207],"three":[22],"phase":[23],"3,":[24],"randomized,":[25],"double-blind,":[26],"vehicle,":[27],"and":[28,35,55,68,103,124,149,166,181,200,223,239,258],"comparator-controlled":[29],"studies":[30],"(Be":[31],"Vivid,":[32],"Be":[33,36,93,158,209],"Ready,":[34],"Sure),":[37],"bimekizumab":[38,116,141,165,179,198,217,221,237,256],"investigated":[40],"the":[42,92,100,115,121,128,140,146,153,157,178,185,197,204,208,243,262],"treatment":[43],"of":[44,74],"psoriasis.":[46],"The":[47],"primary":[48],"efficacy":[49],"end":[50],"point":[51],"psoriatic":[53],"area":[54],"severity":[56],"index":[57],"(PASI)":[58],"90":[59,107,170,228],"(patients":[60],"with":[61,269],"90%":[62],"improvement":[63,85],"PASI":[65,106,169,227],"from":[66,86],"baseline)":[67],"investigator's":[69],"global":[70],"assessment":[71],"(IGA)":[72],"score":[73,108,133,171,190,229,248],"0":[75],"(clear":[76],"skin)-1":[77],"(almost":[78],"clear":[79],"skin)":[80],"as":[81,83],"well":[82,267],"\u22652-point":[84],"baseline":[87],"at":[88],"week":[89],"16.":[90],"Vivid":[94],"study,":[95,160,211],"were":[97,162,213],"randomized":[98,163,214],"into":[99,164,215],"bimekizumab,":[101],"placebo,":[102],"ustekinumab":[104,129,154],"groups.":[105,168],"achieved":[110,135,173,192,231,250],"by":[111,136,174,193,232,251],"85%":[112],"(273/321)":[113],"group,":[117,123,142,148],"5%":[118,143],"(4/83)":[119,144],"placebo":[122,147,167,186,205],"50%":[125],"(81/163)":[126],"group.":[130,155,187,206,226,245,264],"IGA":[131,188,246],"0/1":[132,189,247],"84%":[137],"(270/321)":[138],"53%":[150],"(87/163)":[151],"Ready":[159],"91%":[175],"(317/349)":[176],"group":[180,199],"1%":[182,201],"(1/86)":[183,202],"93%":[194],"(323/349)":[195],"Sure":[210],"two":[216],"groups":[218,238,257],"(receiving":[219],"different":[220],"regimens)":[222],"one":[224],"adalimumab":[225,244,263],"86.2%":[233],"(275/319)":[234],"combined":[236,255],"47.2%":[240],"(75/159)":[241],"85.3%":[252],"(272/319)":[253],"57.2%":[259],"(91/159)":[260],"Bimekizumab":[265],"tolerated":[268],"no":[270],"unexpected":[271],"safety":[272],"findings.":[273]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2024-10-23T00:00:00"}